Professionals

    Resources

    Best Practices for Claim Construction: summarizing current law post Nautilus, Inc. v. Biosig Instruments, Inc. and Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc

    Speaker
    9/25/2017
    Hotel Hilton (Mumbai) and Stellar Gymkhana Greater Noida (Delhi)

    India
    Best Practices for Claim Construction: summarizing current law post Nautilus, Inc. v. Biosig Instruments, Inc. and Teva Pharmaceuticals USA, Inc. v. Sandoz, Inc", Discussion on determining subject matter patentability of method patents in life sciences domain based on Federal Circuit’s decision in Rapid Litigation Management Ltd. v. CellzDirect, Inc. and prior 101 jurisprudence post-Myriad and Review and impact of Mayo, Myriad, and Ariosa decisions on recent USPTO and Federal Circuit decisions addressing 101 rejections for biotech patents